Patients at high risk of invasive fungal infections: when and how to treat.
When and how to treat invasive fungal infections (IFIs) is discussed in this review, with a focus on the two most prevalent non-endemic IFIs, namely invasive aspergillosis and invasive candidiasis. Early treatment initiation in patients with IFIs has a profound impact on mortality rates, but reliable diagnostic measures are lacking. This situation has led to the parallel use of different treatment strategies, e.g. prophylaxis, empirical and pre-emptive treatment, as well as targeted treatment in response to a definite diagnosis of IFI. Identifying high-risk patients is the first step in reducing IFI-related mortality. Patients at risk of invasive aspergillosis comprise (i) those with acute myelogenous leukaemia (AML) or myelodysplastic syndrome (MDS) during remission induction chemotherapy; (ii) patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT); (iii) recipients of solid organ transplants; and (iv) those with other conditions of severe and prolonged immunosuppression. Patients at high risk of invasive candidiasis are less well defined. Risk factors are diverse and include haematological malignancy, neutropenia, age <1 month or >65 years, and recent abdominal surgery. The individual risk further depends on the presence of a variety of other risk factors, including central venous catheters, use of broad spectrum antibacterials, prolonged intensive care unit (ICU) stay, total parenteral nutrition, mucosal Candida spp. colonization and renal failure.Extensive research has been conducted to facilitate the best possible treatment strategies for these severe infections. Optimal timing and choice of antifungal agents largely remain a matter of controversy. After having reviewed the major clinical trials, we conclude that comparisons between different treatment strategies cannot be made, neither at present nor in the near future. The complexity of the clinical problem leads to an eclectic treatment approach to reduce morbidity and mortality from IFIs without compromising tolerability. We recommend prophylaxis with posaconazole for allogeneic HSCT recipients, patients receiving induction chemotherapy for AML or MDS, and those undergoing immunosuppressive therapy for graft-versus-host disease after allogeneic HSCT. For the empirical treatment of persistently febrile neutropenia, caspofungin is our first- and liposomal amphotericin B deoxycholate (LAmB) our second-line choice. Once a diagnosis of invasive aspergillosis has been established, voriconazole should be the preferred treatment option, with LAmB being an alternative. Fluconazole prophylaxis for invasive candidiasis should remain restricted to high-risk ICU patients. Once a diagnosis has been established, the drug of choice for adequate treatment depends largely on neutrophil count and haemodynamic stability. In non-neutropenic patients, an echinocandin should be considered the first-line treatment option, while patients with susceptible Candida spp. may be switched to fluconazole. In neutropenic patients, caspofungin or micafungin might be preferred to anidulafungin as first-line treatment. LAmB is a second-line treatment option in both settings.Early diagnosis of IFIs is imperative to facilitate treatment success. In all patients at risk for IFIs, blood cultures, galactomannan antigen and diagnostic imaging should be rigorously enforced.
Rüping
Maria J G T
MJ
Department I of Internal Medicine, Clinical Trials Unit Infectious Diseases II, Hospital of the University of Cologne, Cologne, Germany.
Vehreschild
Jörg J
JJ
Cornely
Oliver A
OA
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy / Q000473:pathology; D002177:Candidiasis / Q000188:drug therapy / Q000473:pathology; D002986:Clinical Trials as Topic; D003422:Critical Care; D006801:Humans; D009181:Mycoses / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology* / Q000517:prevention & control*; D009503:Neutropenia / Q000150:complications; D012306:Risk
D000935:Antifungal Agents
N Engl J Med. 2007 Jun 14;356(24):2472-82
17568028
J Infect Dis. 2000 Jan;181(1):309-16
10608780
Clin Infect Dis. 2000 Aug;31(2):545-53
10987719
Crit Care Med. 1999 Jun;27(6):1066-72
10397206
Transpl Infect Dis. 2007 Mar;9(1):3-10
17313464
N Engl J Med. 1994 Nov 17;331(20):1325-30
7935701
N Engl J Med. 1992 Mar 26;326(13):845-51
1542320
Am J Med. 1993 Aug;95(2):177-87
8395142
Drug Resist Updat. 2007 Jun;10(3):121-30
17569573
Clin Infect Dis. 2003 Jul 15;37(2):221-9
12856215
Biol Blood Marrow Transplant. 2007 Oct;13(10):1192-200
17889356
Clin Infect Dis. 2005 Nov 1;41(9):1242-50
16206097
J Clin Microbiol. 2007 Jun;45(6):1735-45
17442797
Antimicrob Agents Chemother. 2005 Nov;49(11):4555-60
16251295
Clin Infect Dis. 2002 Apr 1;34(7):909-17
11880955
J Hosp Infect. 2002 Aug;51(4):288-96
12183144
Med Mycol. 2005 May;43(3):235-43
16010850
Infect Control Hosp Epidemiol. 2004 Aug;25(8):624-6
15357151
N Engl J Med. 2007 Jan 25;356(4):348-59
17251531
N Engl J Med. 2002 May 30;346(22):1745-7; author reply 1745-7
12041526
J Antimicrob Chemother. 2006 Apr;57(4):628-38
16459344
Lancet Infect Dis. 2003 Nov;3(11):685-702
14592598
Blood. 2003 May 1;101(9):3365-72
12393455
N Engl J Med. 2002 Jan 24;346(4):225-34
11807146
J Clin Microbiol. 2006 Jun;44(6):1977-81
16757587
Clin Infect Dis. 2006 Jul 1;43(1):25-31
16758414
Eur J Clin Microbiol Infect Dis. 2004 Oct;23(10):739-44
15372315
Blood. 2006 Nov 1;108(9):2928-36
16720833
Lancet. 2007 May 5;369(9572):1519-1527
17482982
Emerg Infect Dis. 2003 Aug;9(8):985-90
12967498
J Hosp Infect. 2002 Aug;51(4):297-304
12183145
J Infect. 2007 Nov;55(5):445-9
17822770
Clin Microbiol Infect. 2002 Jul;8(7):405-12
12199850
Clin Infect Dis. 2004 Feb 1;38(3):311-20
14727199
Crit Care. 2006;10(2):132
16584528
Clin Microbiol Rev. 2007 Jan;20(1):133-63
17223626
Clin Infect Dis. 1995 Nov;21(5):1077-89; quiz 1090-1
8589125
Liver Transpl. 2005 Jun;11(6):656-62
15915482
Clin Infect Dis. 1997 Jun;24(6):1122-8
9195068
N Engl J Med. 2002 Dec 19;347(25):2020-9
12490683
J Clin Microbiol. 2008 Mar;46(3):842-9
18199791
Clin Infect Dis. 2003 Nov 1;37(9):1172-7
14557960
N Engl J Med. 2002 Aug 8;347(6):408-15
12167683
Eur J Clin Microbiol Infect Dis. 2007 Apr;26(4):271-6
17333081
Clin Microbiol Infect. 2008 May;14 Suppl 4:65-70
18430131
Clin Infect Dis. 2008 Aug 1;47(3):427; author reply 427-8
18605908
J Clin Microbiol. 2004 Jul;42(7):3142-6
15243073
Clin Infect Dis. 2002 Jan 1;34(1):7-14
11731939
Am J Respir Crit Care Med. 2004 Sep 15;170(6):621-5
15229094
Intensive Care Med. 2002 Dec;28(12):1708-17
12447512
Transpl Infect Dis. 1999 Dec;1(4):229-36
11428994
J Infect Dis. 1995 Jun;171(6):1545-52
7769290
J Clin Microbiol. 2006 Mar;44(3):760-3
16517851
Crit Care Med. 2003 Mar;31(3):752-7
12626979
J Heart Lung Transplant. 2003 Mar;22(3):258-66
12633692
Clin Infect Dis. 2004 Nov 15;39(10):1407-16
15546073
J Infect Dis. 2002 Nov 1;186(9):1297-306
12402199
Ann Intern Med. 2001 Sep 18;135(6):412-22
11560454
N Engl J Med. 2007 Jan 25;356(4):335-47
17251530
J Antimicrob Chemother. 2005 Sep;56(3):532-7
16040623
Emerg Infect Dis. 2004 Oct;10(10):1713-20
15504255
J Clin Microbiol. 2004 Apr;42(4):1519-27
15070998
Arch Surg. 1971 May;102(5):476-82
5580338
Blood. 2002 May 15;99(10):3554-61
11986207
Am J Med. 1994 Aug;97(2):135-44
8059779
J Clin Microbiol. 2005 Apr;43(4):1829-35
15815004
N Engl J Med. 2004 Sep 30;351(14):1391-402
15459300
Clin Infect Dis. 2008 Feb 1;46(3):327-60
18177225
J Clin Microbiol. 2002 Apr;40(4):1298-302
11923348
Crit Care. 2006 Feb;10(1):R31
16507158
Arch Surg. 1991 Jan;126(1):44-8
1985634
Clin Infect Dis. 2001 Apr 15;32(8):1191-200
11283809
Br J Haematol. 2005 Oct;131(1):22-8
16173959
Antimicrob Agents Chemother. 2007 May;51(5):1818-21
17307977
Clin Infect Dis. 1999 Nov;29(5):1164-70
10524958
Br J Haematol. 2002 Feb;116(2):475-82
11841455
N Engl J Med. 2007 Dec 20;357(25):2601-14
18094380
Ann Surg. 1994 Dec;220(6):751-8
7986142
Eur J Clin Microbiol Infect Dis. 2003 Aug;22(8):457-62
12898283
J Clin Microbiol. 2006 Feb;44(2):529-35
16455909
Am J Transplant. 2004 Nov;4 Suppl 10:110-34
15504225
Clin Microbiol Rev. 2005 Jan;18(1):44-69
15653818
Radiology. 1985 Dec;157(3):611-4
3864189
Crit Care Med. 2006 Mar;34(3):730-7
16505659
Clin Infect Dis. 2001 Jul 15;33(2):177-86
11418877
Liver Transpl. 2002 Nov;8(11):1065-70
12424722
Clin Infect Dis. 1998 Apr;26(4):781-803; quiz 804-5
9564455
Clin Infect Dis. 2007 Oct 1;45(7):883-93
17806055
Intensive Care Med. 2007 Oct;33(10):1679-81
17646965
N Engl J Med. 2002 Jan 24;346(4):278-80
11807153
Clin Infect Dis. 2005 Jul 1;41(1):52-9
15937763
J Trauma. 1979 Oct;19(10):765-7
490691
Diagn Microbiol Infect Dis. 2008 Mar;60(3):273-7
18024053
Expert Opin Pharmacother. 2008 Feb;9(2):175-91
18201143
Lancet. 2005 Oct 22-28;366(9495):1435-42
16243088
Blood. 2001 Mar 15;97(6):1604-10
11238098
Blood. 2002 Dec 15;100(13):4358-66
12393425
Haematologica. 2006 Aug;91(8):1068-75
16885047
Antimicrob Agents Chemother. 2005 Sep;49(9):3640-5
16127033
N Engl J Med. 1999 Mar 11;340(10):764-71
10072411
Curr Opin Infect Dis. 2006 Dec;19(6):571-6
17075333
Drugs. 2007;67(11):1567-601
17661528
Clin Infect Dis. 2007 May 15;44(10):1289-97
17443465
Eur J Clin Microbiol Infect Dis. 1994 Oct;13(10):797-804
7889948
Ann Surg. 2001 Apr;233(4):542-8
11303137
Medicine (Baltimore). 2000 Jul;79(4):250-60
10941354
J Clin Microbiol. 2004 Jan;42(1):435-8
14715799
Clin Infect Dis. 1993 May;16(5):677-88
8507760
Ann Hematol. 2003 Oct;82 Suppl 2:S118-26
13680172
J Clin Microbiol. 2005 Sep;43(9):4434-40
16145088
Clin Diagn Lab Immunol. 2003 Sep;10(5):882-5
12965921
Br J Haematol. 2006 Jan;132(1):3-12
16371014
Lancet Infect Dis. 2003 Mar;3(3):156-61
12614732
J Antimicrob Chemother. 2003 Jul;52(1):71-7
12775680
Clin Infect Dis. 2004 Aug 1;39(3):309-17
15306996
Clin Infect Dis. 2003 Sep 1;37(5):634-43
12942393
Liver Transpl. 2006 May;12(5):850-8
16628697
Ann Hematol. 2003 Oct;82 Suppl 2:S105-17
13680173
J Infect. 1991 Jan;22(1):45-52
1848268
Medicine (Baltimore). 2003 Sep;82(5):309-21
14530780
Clin Infect Dis. 2006 Apr 1;42(7):955-63
16511759
Crit Care Med. 2004 Dec;32(12):2443-9
15599149
Intensive Care Med. 2005 Nov;31(11):1479-87
16172847
Diagn Microbiol Infect Dis. 1999 Aug;34(4):281-6
10459478
J Clin Microbiol. 2002 Sep;40(9):3489-92
12202600
Am J Transplant. 2004 May;4(5):796-802
15084177
J Antimicrob Chemother. 2006 Feb;57(2):317-25
16339606
Clin Infect Dis. 2005 Sep 15;41 Suppl 6:S389-93
16108005
Clin Infect Dis. 2001 Oct 15;33(8):e83-90
11550120
Transplantation. 2004 Apr 27;77(8):1260-4
15114095
Surg Infect (Larchmt). 2003 Winter;4(4):345-54
15012861
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
18462102
Clin Infect Dis. 2007 Feb 1;44(3):373-9
17205443
Antimicrob Agents Chemother. 2005 Feb;49(2):512-7
15673726
Arch Intern Med. 1989 Oct;149(10):2349-53
2802900
Lancet Infect Dis. 2005 Oct;5(10):609-22
16183515